NCT00259090View on ClinicalTrials.gov

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

500 mg intramuscular injection

DRUG

Anastrazole

oral tablet

Trial Locations (1)

Unknown

Research Site, Nottingham

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00259090 - Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer | Biotech Hunter | Biotech Hunter